# Veterans Push Congress on Cannabis & Psychedelics Access (Newsletter: March 9, 2026) > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/veterans-medical-cannabis-amendment-congress-2026/ > **Published:** 2026-03-09T17:30:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:09:59-04:00 > **Clinical Summary:** Explore the veterans medical cannabis amendment and its impact on access to cannabis and psychedelics for treatment-resistant conditions. --- ✦ New CED Clinical Relevance** #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyMental HealthResearchSafety Why This Matters Clinicians treating veterans for PTSD, [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), and other service-related conditions need to understand evolving federal policy on cannabis and psychedelics access, as congressional pressure may expand treatment options currently unavailable through VA systems. Veterans’ advocacy for these therapies reflects growing patient demand and emerging evidence of efficacy, requiring clinicians to stay informed about potential regulatory changes that could shift standard of care recommendations. Policy shifts at the federal level would directly impact prescribing practices, insurance coverage, and clinical guidance that clinicians must communicate to veteran patients seeking alternative or adjunctive treatments. Clinical Summary Veterans’ advocacy groups are increasingly pressuring Congress to expand access to cannabis and psychedelics for treatment-resistant conditions, particularly PTSD and [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), citing preliminary evidence of efficacy in this population. Concurrent with these policy efforts, emerging [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) demonstrates that cannabidiol (CBD) and tetrahydrocannabinol (THC) exert potent pharmacological effects that may address symptoms inadequately controlled by conventional therapies, though robust randomized controlled trials remain limited. The regulatory and legislative landscape is shifting as more jurisdictions, including the Isle of Man, establish medical cannabis clinics and clinical frameworks, potentially influencing U.S. policy decisions and research funding priorities. For clinicians, these developments signal growing institutional recognition of cannabis as a potential therapeutic option for specific patient populations, though prescribing remains constrained by federal scheduling and lack of standardized dosing guidelines. Veterans and other patient groups with treatment-resistant conditions may increasingly request [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/), requiring clinicians to develop evidence-informed counseling approaches even as federal policy continues to evolve. Clinicians should monitor ongoing advocacy efforts and emerging clinical evidence to anticipate potential changes in their ability to discuss, recommend, or refer patients for [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). Dr. Caplan’s Take “What we’re seeing with veterans advocating for cannabis access is a recognition of something I’ve observed clinically for two decades: these compounds can meaningfully reduce PTSD symptoms and chronic pain in patients who’ve exhausted conventional options, and the evidence base, while still imperfect, is now sufficient to warrant clinical access rather than continued prohibition.” Clinical Perspective ?️ While anecdotal reports from veteran advocacy groups highlight growing interest in cannabis and psychedelics for conditions like PTSD and chronic pain, clinicians should recognize that the evidence base remains limited and heterogeneous, with most high-quality trials focusing on specific cannabinoid formulations rather than whole-plant products or illicit psychedelics. The gap between patient demand and regulatory approval reflects real uncertainty about efficacy, optimal dosing, long-term safety, and potential drug interactions, particularly in veterans who may have complex medication regimens or comorbid conditions. Political momentum toward access does not necessarily reflect clinical readiness, and early enthusiasm must be tempered by the confounding effects of therapeutic expectation, publication bias favoring positive results, and the challenge of conducting rigorous trials in politically charged contexts. Clinicians caring for veterans should acknowledge legitimate suffering while maintaining evidence-based skepticism, staying informed about emerging research through peer-reviewed sources, and 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Veterans+push+Congress+on+cannabis+%26amp%3B+psychedelics+access+%28Newsletter%3A+March+9%2C+2026%29+%40drcaplan&url=https%3A%2F%2Fwww.marijuanamoment.net%2Fveterans-push-congress-on-cannbis-psychedelics-access-newsletter-march-9-2026%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.marijuanamoment.net%2Fveterans-push-congress-on-cannbis-psychedelics-access-newsletter-march-9-2026%2F) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Veterans+push+Congress+on+cannabis+%26amp%3B+psychedelics+access+%28Newsletter%3A+March+9%2C+2026%29+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.marijuanamoment.net%2Fveterans-push-congress-on-cannbis-psychedelics-access-newsletter-march-9-2026%2F) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Daily Digest: Last 2 Hours: Stroke Risk, Industry Maturation, and Reassurance for Older Adults — March 09, 2026](https://cedclinic.com/daily-digest-last-2-hours-stroke-risk-industry-maturation-and-reassurance-for-older-adults-march-09-2026/) - [Daily Digest: Last 6 Hours: Cognitive Safety, Liver Disease Breakthroughs, and the Drug Testing Problem That Won’t Go Away — March 06, 2026](https://cedclinic.com/cannabis-cognitive-aging-liver-disease-drug-testing-issues/) - [Veterans Groups Urge Congress To Expand Psychedelics And Marijuana** Access To …](https://cedclinic.com/veterans-cannabis-psychedelic-therapy-access-expansion/) 📰 Source: [https://www.marijuanamoment.net/veterans-push-congress-on-cannbis-psychedelics-access-newsletter-march-9-2026/](https://www.marijuanamoment.net/veterans-push-congress-on-cannbis-psychedelics-access-newsletter-march-9-2026/) Further Reading Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Congress considers veterans’ medical cannabis amendment (Newsletter: May 8, 2026)](https://cedclinic.com/congress-considers-veterans-medical-cannabis-amendment-newsletter-may-8-2026/) An update on congressional discussions about expanding medical cannabis access for veterans, highlighting legislative progress and challenges. [Read More](https://cedclinic.com/congress-considers-veterans-medical-cannabis-amendment-newsletter-may-8-2026/) [Joe Rogan praises Trump's executive order on psychedelics research | Watch – MSN](https://cedclinic.com/psychedelic-research-funding-impact-trump-executive-order/) Coverage of federal executive actions supporting psychedelics research, relevant to veterans' access advocacy. [Watch Now](https://cedclinic.com/psychedelic-research-funding-impact-trump-executive-order/) [Trump administration reclassifies cannabis in major shift that could expand scientific research – MSN](https://cedclinic.com/federal-cannabis-reclassification-medical-research/) Details on cannabis reclassification efforts that may influence veterans' access and research opportunities. [Learn More](https://cedclinic.com/federal-cannabis-reclassification-medical-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).